EDTA vs placebo
Maximum walking distance · atherosclerotic cardiovascular disease
1 finding from 1 review
- no estimate extracted2 studies · 165 participantsLow
Findings
What do systematic reviews say?
4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only
No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%
Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Botulinum toxin type A vs placebo
Cervical dystonia‐specific improvement · cervical dystonia
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
Botulinum toxin type A vs placebo
Adverse events at 4 weeks; 1085 participants (8 RCTs) · cervical dystonia
Botulinum toxin type A probably leads to higher adverse events at 4 weeks; 1085 participants (8 RCTs) compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.23 [1.05, 1.43]Studies not reportedModerate
Botulinum toxin type A vs placebo
Subjective participant assessment at 4 weeks; 755 participants(6 RCTs) · cervical dystonia
Botulinum toxin type A leads to higher subjective participant assessment at 4 weeks; 755 participants(6 RCTs) compared with placebo (high certainty).
1 finding from 1 review
- RR 2.19 [1.78, 2.7]Studies not reportedHigh
Botulinum toxin type A vs placebo
Cervical dystonia‐specific pain · cervical dystonia
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
Botulinum toxin type A vs placebo
Tolerability assessed as dropouts at 4 to 6 weeks: 705 participants (5 RCTs) · cervical dystonia
Botulinum toxin type A leads to lower tolerability assessed as dropouts at 4 to 6 weeks: 705 participants… compared with placebo (high certainty).
1 finding from 1 review
- RR 0.48 [0.32, 0.73]Studies not reportedHigh
Botulinum toxin type A vs placebo
Health‐related quality of life · cervical dystonia
1 finding from 1 review
- no estimate extractedStudies not reportedModerate
Botulinum toxin type A vs placebo
Duration of effect 618 participants (5 RCTs) · cervical dystonia
It is very uncertain whether botulinum toxin type A changes duration of effect 618 participants (5 RCTs) compared with placebo (very low certainty).
1 finding from 1 review
- no estimate extractedStudies not reportedVery low
HALOPERIDOL vs placebo
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
- MD 0.341 study · 133 participantsLow
HALOPERIDOL vs RISPERIDONE
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
HALOPERIDOL vs OLANZAPINE
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium within 24 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
- MD 2.361 study · 28 participantsVery low
HALOPERIDOL vs OLANZAPINE
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes symptoms of delirium between 24 and 48 hoursa compared with olanzapine (very low certainty).
1 finding from 1 review
- MD 1.91 study · 24 participantsVery low
HALOPERIDOL vs OLANZAPINE
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
- no estimate extractedStudies not reportedNo studies found
- no estimate extractedStudies not reportedNo studies found
HALOPERIDOL vs OLANZAPINE
Adverse events including extrapyramidal effects · terminally ill adults with delirium
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
RISPERIDONE vs placebo
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium within 24 hoursa compared with placebo (low certainty).
1 finding from 1 review
- MD 0.761 study · 129 participantsLow
RISPERIDONE vs placebo
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review
- MD 0.851 study · 111 participantsLow
RISPERIDONE vs placebo
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
- no estimate extractedStudies not reportedNo studies found
- no estimate extracted1 study · 111 participantsLow
HALOPERIDOL vs placebo
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with placebo (low certainty).
1 finding from 1 review
- MD 0.491 study · 123 participantsLow
RISPERIDONE vs placebo
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: risperidone showed no clear difference in adverse events including extrapyramidal effectsd compared with placebo (low certainty).
1 finding from 1 review
- MD 0.731 study · 111 participantsLow
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol
Symptoms of delirium within 24 hoursa · terminally ill adults with severe delirium
It is very uncertain whether summary of findings: lorazepam plus haloperidol changes symptoms of delirium within 24 hoursa compared with placebo plus haloperidol (very low certainty).
1 finding from 1 review
- MD 2.11 study · 50 participantsVery low